December 30, 2013

Genzyme Receives Complete Response Letter from FDA on LemtradaTM (alemtuzumab) Application

 

Genzyme Receives Complete Response Letter from FDA on LemtradaTM (alemtuzumab) Application

Paris, France – December 30, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its supplemental Biologics License Application seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.